TABLE 2.
Identification of rifampicin and isoniazid resistance-associated mutations from Mycobacterium tuberculosis complex DNA-positive samples by the cobas MTB-RIF/INH assaya
| Drug | No. of samples/total (% [95% CI]) |
|||
|---|---|---|---|---|
| Sensitivity |
Specificity | |||
| Smear-positive | Smear-negative | Pooled | ||
| Rifampicin | 36/40 (90.0 [76.9, 96.0]) | 2/3 (66.7 [20.8, 93.9]) | 38/43 (88.4 [75.5, 94.9]) | 40/41 (97.6 [87.4, 99.6]) |
| Isoniazid | 32/42 (76.2 [61.5, 86.5]) | 4/5 (80.0 [37.6, 96.4]) | 36/47 (76.6 [62.8, 86.4]) | 38/38 (100.0 [90.8, 100.0]) |
a
A combination of phenotypic and molecular (line probe assays) drug susceptibility testing performed from cultures was used as a composite reference standard. CI, confidence interval.